A study on the retrospective analysis of the registry of the High-Risk Breast and Ovarian Cancer Program of a single private clinical center in Chile (years 2008–2018) demonstrated that most variants (81.8%) in 315 women were in BRCA1 or BRCA2, and that 10.5% of cases were carriers of a pathogenic or probably pathogenic variant in genes other than BRCA1/2, such as RAD51C, RAD51D, ATM, PALB2, CHEK2, and CDH1 [54]. Here, BRCA2 is linked to ovarian carcinoma.